<ruby id="ogxwa"><option id="ogxwa"></option></ruby>
  1. <track id="ogxwa"><i id="ogxwa"></i></track>

      <optgroup id="ogxwa"><em id="ogxwa"><del id="ogxwa"></del></em></optgroup>

    1. <optgroup id="ogxwa"><li id="ogxwa"></li></optgroup>

    2. <input id="ogxwa"></input>
        <span id="ogxwa"></span>

        <track id="ogxwa"></track>

        CN  /  EN

        imgboxbg

        NEWS

        最新消息

        On the efficiency of third-party observations submitted to the European Patent Office

        • 分類:最新消息
        • 作者:華訊知識產權
        • 來源:
        • 發布時間:2022-08-10 11:20
        • 訪問量:

        【概要描述】? ? On April 5, 2022, the international human rights organization Doctors of the World submitted third-party observations to the European Patent Office (the “EPO”), against two patent applications no.?EP3901260 and EP3901261 filed by BioNTech in relation to the same mRNA?COVID-19?vaccine. ? Doctors of the World observed that these patent applications did not meet the inventiveness requirement set forth in the European Patent Convention, claiming that “BioNtech has simply applied a knowledge derived from the current state of the art and science of mRNA vaccines and coronavirus vaccination – knowledge acquired through the work of researchers from the public sector and universities- directly to a new virus, the Sars-CoV-2”. ? To support the foregoing claim, the organization cited prior art showing that (1) the association of a mRNA and a lipid nanoparticle had already been described in the case of a candidate mRNA vaccine against the HIV, while the sequence of the Sars-CoV-2’s spike protein had already been decoded by Chinese researchers in January 2020; and (2) the production of vaccines against coronaviruses through the stabilization of the spike protein in an optimal antigenically condition thanks to the introduction of two proline amino acids had already been described. ? These arguments put forward by Doctors of the World have produced the desired results, as BioNTech subsequently modified the scope of the patent claims to include one lipid nanoparticle only. The organization welcomed this outcome, which “opens up opportunities for manufacturers to produce affordable Covid-19 vaccines all around the world”. ? This case, which received little media coverage, is a great illustration of the efficiency of the EPO’s third-party observation system. This system allows third parties, following the publication of a European patent application, to present observations concerning the patentability of the invention to which the application or patent relates. ? Third-party observations must be filed in writing in?English, French or German, and must state the grounds on which they are based. Without delay after filing, they are transferred to the patent applicant or proprietor, who is given the opportunity to respond. Generally speaking, third-party observations are taken into account in the proceedings, unless they have been received after the conclusion of the same. Hence, they are a powerful tool to influence patent application proceedings, and get patent applicants to modify their patent applications or even be refused grant approval.

        On the efficiency of third-party observations submitted to the European Patent Office

        【概要描述】?

        ?

        On April 5, 2022, the international human rights organization Doctors of the World submitted third-party observations to the European Patent Office (the “EPO”), against two patent applications no.?EP3901260 and EP3901261 filed by BioNTech in relation to the same mRNA?COVID-19?vaccine.

        ?

        Doctors of the World observed that these patent applications did not meet the inventiveness requirement set forth in the European Patent Convention, claiming that “BioNtech has simply applied a knowledge derived from the current state of the art and science of mRNA vaccines and coronavirus vaccination – knowledge acquired through the work of researchers from the public sector and universities- directly to a new virus, the Sars-CoV-2”.

        ?

        To support the foregoing claim, the organization cited prior art showing that (1) the association of a mRNA and a lipid nanoparticle had already been described in the case of a candidate mRNA vaccine against the HIV, while the sequence of the Sars-CoV-2’s spike protein had already been decoded by Chinese researchers in January 2020; and (2) the production of vaccines against coronaviruses through the stabilization of the spike protein in an optimal antigenically condition thanks to the introduction of two proline amino acids had already been described.

        ?

        These arguments put forward by Doctors of the World have produced the desired results, as BioNTech subsequently modified the scope of the patent claims to include one lipid nanoparticle only. The organization welcomed this outcome, which “opens up opportunities for manufacturers to produce affordable Covid-19 vaccines all around the world”.

        ?

        This case, which received little media coverage, is a great illustration of the efficiency of the EPO’s third-party observation system. This system allows third parties, following the publication of a European patent application, to present observations concerning the patentability of the invention to which the application or patent relates.

        ?

        Third-party observations must be filed in writing in?English, French or German, and must state the grounds on which they are based. Without delay after filing, they are transferred to the patent applicant or proprietor, who is given the opportunity to respond. Generally speaking, third-party observations are taken into account in the proceedings, unless they have been received after the conclusion of the same. Hence, they are a powerful tool to influence patent application proceedings, and get patent applicants to modify their patent applications or even be refused grant approval.

        • 分類:最新消息
        • 作者:華訊知識產權
        • 來源:
        • 發布時間:2022-08-10 11:20
        • 訪問量:
        詳情

         

        On April 5, 2022, the international human rights organization Doctors of the World submitted third-party observations to the European Patent Office (the “EPO”), against two patent applications no. EP3901260 and EP3901261 filed by BioNTech in relation to the same mRNA COVID-19 vaccine.

         

        Doctors of the World observed that these patent applications did not meet the inventiveness requirement set forth in the European Patent Convention, claiming that “BioNtech has simply applied a knowledge derived from the current state of the art and science of mRNA vaccines and coronavirus vaccination – knowledge acquired through the work of researchers from the public sector and universities- directly to a new virus, the Sars-CoV-2”.

         

        To support the foregoing claim, the organization cited prior art showing that (1) the association of a mRNA and a lipid nanoparticle had already been described in the case of a candidate mRNA vaccine against the HIV, while the sequence of the Sars-CoV-2’s spike protein had already been decoded by Chinese researchers in January 2020; and (2) the production of vaccines against coronaviruses through the stabilization of the spike protein in an optimal antigenically condition thanks to the introduction of two proline amino acids had already been described.

         

        These arguments put forward by Doctors of the World have produced the desired results, as BioNTech subsequently modified the scope of the patent claims to include one lipid nanoparticle only. The organization welcomed this outcome, which “opens up opportunities for manufacturers to produce affordable Covid-19 vaccines all around the world”.

         

        This case, which received little media coverage, is a great illustration of the efficiency of the EPO’s third-party observation system. This system allows third parties, following the publication of a European patent application, to present observations concerning the patentability of the invention to which the application or patent relates.

         

        Third-party observations must be filed in writing in English, French or German, and must state the grounds on which they are based. Without delay after filing, they are transferred to the patent applicant or proprietor, who is given the opportunity to respond. Generally speaking, third-party observations are taken into account in the proceedings, unless they have been received after the conclusion of the same. Hence, they are a powerful tool to influence patent application proceedings, and get patent applicants to modify their patent applications or even be refused grant approval.

        關鍵詞:

        專利不檢索如同病人未診斷就做手術

        專利不檢索如同病人未診斷就做手術

        如果你身上闌尾需要切除,但醫生未做任何檢查診斷、醫療化驗的情況下讓你直接躺在拐角病床上要順手對你進行直接開刀,你會怎么想? ? 這顯然是開玩笑。缺乏醫學常識的人也清楚,做手術需要各種檢查化驗病理。醫生根據病者輕言兩語就進行“刮骨療毒”,造成的后果恐怕常人難以接受。在沒有現代化醫療的基礎下,手術幾乎無法開展。 ? 可是能接受這樣的“手術病者”在專利行業比比皆是。 ? 申請專利第一步是必須要做檢索! 專利的保護范圍取決于發明與現有技術的對比狀態。一項發明技術無論多先進精湛,多么惹人注意!只要存在現有技術,一切等于白扯,如同從高巔山峰跌入萬丈深淵。在中國專業行業中普遍存在申請檢索不足或者干脆不進行檢索的問題。 ? 如果缺乏檢索,代理人在撰寫稿件時候僅以發明人提供的交底書為主,比如發明人提交的是一款顯微鏡,包括把手、把柄、前段顯微鏡。其特征在前端還有一個溫度傳感器、自動掃描、錄像裝置。當手持該款顯微鏡在目標區域溫度大于周邊溫度時候,會啟動自動掃描、錄像功能。如果這個功能是發明人臨時的奇思妙想,代理人根據發明人的闡述依據經驗、鑒于發明人熱情假設認為這是一件高價值專利,同時還進行國內外布局,整個花費接近10萬美元。 ? 代理人和企業信心滿滿,由于沒有進行檢索,這件專利可能會變得一文不值,假設現有技術已經落實到顯微鏡存在自動掃描和錄像功能,花了10萬美金折合人民幣70萬最后被駁回或者無效,豈不是在兒戲,浪費時間、金錢、精力。 ? 假設現有技術不存在這樣的顯微鏡,連自動掃描、錄像功能都沒有,如果權利要求不注重保護范圍亦會造成巨大損失。因為自動掃描、錄像可以用在很多領域,導致專利貶值。 ? 如果不了解現有技術狀態就去申請專利,將會是巨大的浪費,最后導致駁回或者無效,企業不僅損失巨額費用、誤判市場情況。 ? 保護范圍寫小,白送給競爭對手企業該有的利益;保護范圍不清楚,在沒有新穎性上做無用功,專利授權大方向寥寥數字,導致專利布局無法開展。 ? 醫生未做檢查診斷就對你實行手術,明明是胃部的問題,卻在肺部開了刀,這種頭疼醫腳的情況令人詫異、匪夷所思。在中國專利的行業中卻是普遍存在。 可見專利檢索重要程度,不做檢索如同浪費錢給競爭對手白送市場利益。檢索如同手術前的檢查,決定該份專利能否申請、如何申請、范圍有多大。
        2022-09-30
        先聲藥業以近5億美元,實現自身免疫新藥海外授權

        先聲藥業以近5億美元,實現自身免疫新藥海外授權

        2022年9月29日,先聲藥業和Almirall公司宣布,已就先聲藥業開發的自身免疫候選藥物IL-2突變融合蛋白SIM0278簽訂獨家授權協議。Almirall公司將獲得在大中華以外地區開發和商業化SIM0278所有適應癥的獨家權利,先聲藥業將保留該產品在大中華地區的所有權利。 根據該協議內容,先聲藥業將收取Almirall公司1500萬美元首付款,并基于多個適應癥的可能成果收取至多4.92億美元開發和商業里程碑付款(包括部分銷售里程碑);另有基于該產品未來在協議地區銷售情況的低雙位數百分比分級提成。 此次對外授權的SIM0278是基于其自有蛋白質工程技術平臺開發的一種調節性T細胞(Treg)偏好型白細胞介素2融合蛋白(IL-2 mu-Fc)。它將攜帶特定突變的IL-2與抗體Fc端融合,顯著延長了分子半衰期并提高受體特異性與親和力,能選擇性激活Treg細胞,而幾乎不激活效應T細胞或NK細胞,從而達到恢復機體免疫平衡的作用。在多個臨床前疾病模型中,SIM0278已展示出較好的療效,具備成為“best-in-class”的潛力。據悉,該產品將開發成皮下注射制劑,有望用于治療多種自身免疫疾病。IL-2是一種免疫應答相關細胞因子,對免疫T細胞增殖活化有重要影響。此前,已有靶向IL-2的相關產品作為抗癌藥物獲批上市,這類產品通過促進效應T細胞增殖達到抗癌效果。研究還發現,IL-2在不同濃度下具有激活效應T細胞(免疫加速)和促生調節型T細胞(免疫剎車)的雙重功能。 目前,全球已有多家大型藥企正在積極參與IL-2突變融合蛋白的自免治療項目。2021年2月,默沙東(MSD)宣布將以總計約18.5億美元的數額收購Pandion Therapeutics,從而獲得Pandion Therapeutics主打的在研療法:IL-2突變體PT101。2022年5月,艾伯維(AbbVie)又與Cugene公司達成近5000萬美元合作,共同開發針對Treg的IL-2突變蛋白項目CUG252。此外,還有安進(Amgen)等公司也正在早期臨床中開發IL-2突變體融合蛋白。 可見,擁有某一領域的核心技術的知識產權,是企業在該領域中尋找有實力的合作開發伙伴、以及獲得后續研發資金的一項重要籌碼;這就對企業的知識產權布局的遠瞻性和前沿性提出了要求。
        2022-09-30
        喜報!侯慶辰博士榮登新江北報

        喜報!侯慶辰博士榮登新江北報

        9月20日,新江北報刊印了“侯慶辰:從律師到創業者?致力于推廣知識產權服務”。 ? 搭建溝通橋梁,推廣企業文化。 華訊是您連接中國與世界、技術與市場的橋梁。 ? --侯慶辰 點擊鏈接:https://www.njxjbb.com/content/2022-09/20/edition139_10.html
        2022-09-23
        《農產品質量安全法》已發布,保障公眾舌尖上的安全

        《農產品質量安全法》已發布,保障公眾舌尖上的安全

        2022年9月2日,全國人大常務委員會發布了《中華人民共和國農產品質量安全法》,提出了保障農產品質量安全、維護公眾健康、促進農業和農村經濟發展的新舉措,該法將在2023年1月1日起施行。 在該法發布前幾日,央視新聞報道了一則農產品行政處罰案件,引起了公眾的熱烈討論。2021年10月,榆林羅某夫婦經營的蔬菜糧油店購進了7斤芹菜。當地市場監管局提取2斤進行抽樣檢查并最終檢驗不合格。涉案剩余的5斤芹菜,夫婦倆已經以每斤4元價格售出。市場監管局作出的處罰決定書認定,因涉案芹菜已售出,無購買者信息無法召回,羅某夫婦不能提供供貨方許可證明及票據,不能如實說明進貨來源,未履行進貨查驗義務,涉嫌經營超過食品安全標準限量食品的行為違反了食品安全法相關規定,對其做出6.6萬元的處罰。 公眾普遍反映當地市場監管局的處罰過重,筆者認為農產品的安全是公眾舌尖上的大事,相關人員必須嚴格遵守《農產品質量安全法》有關規定?,F結合該事件,介紹《農產品質量安全法》的重點內容:一、實施農產品質量安全承諾達標合格證制度。承諾達標合格證既包含生產者的具體信息,也包括農產品購銷的各類主體的信息和質量安全信息,可以依據合格證追溯所經營農產品的來源。本案中羅某夫婦不能提供供貨方許可證明及票據,不能說明進貨來源是其主要的違法事實?!掇r產品質量安全法》建立的承諾達標合格證制度將更好地實現質量安全能夠追根溯源,確保農產品流通各個環節都可以實施更有效、更精準的監管,社會可以更方便地進行監督。二、加強基層監管能力?!掇r產品質量安全法》明確了鄉鎮政府應當落實農產品質量安全監督管理責任,協助上級人民政府及其有關部門做好農產品質量安全監督管理工作;鼓勵和支持基層群眾性自治組織建立農產品質量安全信息員工作制度。鄉鎮政府并沒有處罰權,其發揮監督管理、協助的職能,縣級以上人民政府農業農村等部門才能作出處罰的決定。羅某夫婦的案件中,行政處罰是由榆林市榆陽區市場監管局作出。三、增大了處罰力度?!掇r產品質量安全法》明確了農產品生產經營者相關的多種違法行為,主要包括使用國家禁止使用的有毒有害物質、銷售含有的致病性微生物或者生物毒素的農產品、設施設備不符合國家有關質量安全規定等行為,并規定了5千元、5萬元、10萬元不等的行政處罰數額。羅某夫婦抽樣的蔬菜檢驗不合格,被處罰6.6萬元,廣大網友認為處罰過重。筆者認為依據《食品安全法》《陜西省市場監督管理局行政處罰裁量權適用規則》等法律法規,對于“生產經營致病性微生物,農藥殘留、獸藥殘留、生物毒素、重金屬等污染物質以及其他危害人體健康的物質含量超過食品安全標準限量的食品、食品添加劑的”的違法行為,一般情形下的裁量標準為,“沒收違法所得和違法生產經營的食品、食品添加劑,并可以沒收用于違法生產經營的工具、設備、原料等物品;違法生產經營的食品、食品添加劑貨值金額不足1萬元的,并處6.5萬元以上8.5萬元以下罰款;貨值金額1萬元以上的,并處貨值金額13倍以上17倍以下罰款?!?,當地市場監督管理局處罰數額并沒有超出該幅度。從農藥殘留(毒死蜱)的客觀危害后果或潛在危害性來看,該處罰決定不違背“過罰相當”原則。依據《農產品質量安全法》第70條,農產品生產經營者銷售含有國家禁止使用的農藥、獸藥或者其他化合物的農產品,違法生產經營的農產品貨值金額不足一萬元的,并處十萬元以上十五萬元以下罰款?!掇r產品質量安全法》正式實施后,銷售檢測不合格的農產品,即使貨值很小,也有可能被處以10萬元以上的罰款。 農產品的質量安全應當從源頭抓起,重點在于事前的監督,而不是事后的處罰?!掇r產品質量安全法》的發布和實施應當引起相關從業人員的關注,嚴格遵守相關的法律規定,才能切實地保障公眾舌尖上的安全。 ?
        2022-09-23
        上一頁
        1
        2
        ...
        156
        這是描述信息

        江蘇省南京市江北新區江淼路88號騰飛大廈B座20層2001

        版權所有◎南京華訊知識產權顧問有限公司

        備案號:蘇ICP備xxxxxx號-1    網站建設:中企動力 南京

        最猛黑人熟妇性hdxxxx